Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

Marina T. Van Leeuwen, Steven Luu, Howard Gurney, Martin R. Brown, Kate Webber, Sallie-Anne Pearson, Lee Hunt, Claire M. Vajdic

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Introduction: The introduction of targeted therapies for cancer has contributed to dramatic improvements in patient survival. Nevertheless, several targeted therapies have been associated with 'off-target' adverse effects, based on varying levels of evidence. To date, this evidence has not been systematically synthesised. We will synthesise published systematic review evidence of cardiovascular toxicity associated with targeted cancer therapies. Methods and analysis: We will include systematic reviews of randomised controlled trials and observational studies that report on cardiovascular outcomes for individual agents. We will identify systematic reviews by applying predeveloped, standardised search strategies within Embase, Medline and Cochrane Central. Two independent reviewers will identify reviews published up to 31 December 2016 using predefined eligibility criteria. They will resolve ambiguous cases through consensus, arbitrated by a third reviewer if required. The reviewers will extract and report data according to methodological guidelines for overviews provided by the Cochrane Collaboration, Joanna Briggs Institute and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. They will assess the quality of included reviews by applying the Assessment of Multiple Systematic Reviews tool. They will judge the quality of evidence in included reviews based on their assessment of bias and incorporation into the interpretation of findings. In synthesising the evidence, we will classify agents based on systematic review evidence of toxicity (sufficient, probable, possible or indeterminate) for specific cardiovascular outcomes (congestive heart failure, myocardial infarction, ischaemic heart disease, left ventricular ejection fraction decline, cerebrovascular disease, pulmonary embolism, thrombosis and hypertension). This will provide clinicians and patients with an accessible synthesis based on robust methodology. Ethics and dissemination: Ethics approval is not required for overviews. We will conduct the study in collaboration with consumer representatives. We will submit results for peer-review publication, and disseminate them through established clinical and consumer networks. PROSPERO registration number: CRD42017080014.

LanguageEnglish
Article numbere021064
Pages1-6
Number of pages6
JournalBMJ Open
Volume8
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018

Fingerprint

Ethics
Embolism and Thrombosis
Cerebrovascular Disorders
Neoplasms
Peer Review
Pulmonary Embolism
Pulmonary Hypertension
Stroke Volume
Observational Studies
Myocardial Ischemia
Publications
Meta-Analysis
Consensus
Therapeutics
Randomized Controlled Trials
Heart Failure
Myocardial Infarction
Guidelines
Survival

Bibliographical note

Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • antineoplastic agent
  • cancer
  • cardiovascular toxicity
  • overview
  • systematic review
  • targeted therapy

Cite this

Van Leeuwen, Marina T. ; Luu, Steven ; Gurney, Howard ; Brown, Martin R. ; Webber, Kate ; Pearson, Sallie-Anne ; Hunt, Lee ; Vajdic, Claire M. / Cardiovascular toxicity of targeted therapies for cancer : a protocol for an overview of systematic reviews. In: BMJ Open. 2018 ; Vol. 8, No. 6. pp. 1-6.
@article{ce998d7aac394564ab33a225291b12ac,
title = "Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews",
abstract = "Introduction: The introduction of targeted therapies for cancer has contributed to dramatic improvements in patient survival. Nevertheless, several targeted therapies have been associated with 'off-target' adverse effects, based on varying levels of evidence. To date, this evidence has not been systematically synthesised. We will synthesise published systematic review evidence of cardiovascular toxicity associated with targeted cancer therapies. Methods and analysis: We will include systematic reviews of randomised controlled trials and observational studies that report on cardiovascular outcomes for individual agents. We will identify systematic reviews by applying predeveloped, standardised search strategies within Embase, Medline and Cochrane Central. Two independent reviewers will identify reviews published up to 31 December 2016 using predefined eligibility criteria. They will resolve ambiguous cases through consensus, arbitrated by a third reviewer if required. The reviewers will extract and report data according to methodological guidelines for overviews provided by the Cochrane Collaboration, Joanna Briggs Institute and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. They will assess the quality of included reviews by applying the Assessment of Multiple Systematic Reviews tool. They will judge the quality of evidence in included reviews based on their assessment of bias and incorporation into the interpretation of findings. In synthesising the evidence, we will classify agents based on systematic review evidence of toxicity (sufficient, probable, possible or indeterminate) for specific cardiovascular outcomes (congestive heart failure, myocardial infarction, ischaemic heart disease, left ventricular ejection fraction decline, cerebrovascular disease, pulmonary embolism, thrombosis and hypertension). This will provide clinicians and patients with an accessible synthesis based on robust methodology. Ethics and dissemination: Ethics approval is not required for overviews. We will conduct the study in collaboration with consumer representatives. We will submit results for peer-review publication, and disseminate them through established clinical and consumer networks. PROSPERO registration number: CRD42017080014.",
keywords = "antineoplastic agent, cancer, cardiovascular toxicity, overview, systematic review, targeted therapy",
author = "{Van Leeuwen}, {Marina T.} and Steven Luu and Howard Gurney and Brown, {Martin R.} and Kate Webber and Sallie-Anne Pearson and Lee Hunt and Vajdic, {Claire M.}",
note = "Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2018",
month = "6",
day = "1",
doi = "10.1136/bmjopen-2017-021064",
language = "English",
volume = "8",
pages = "1--6",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "British Medical Journal Publishing Group",
number = "6",

}

Cardiovascular toxicity of targeted therapies for cancer : a protocol for an overview of systematic reviews. / Van Leeuwen, Marina T.; Luu, Steven; Gurney, Howard; Brown, Martin R.; Webber, Kate; Pearson, Sallie-Anne; Hunt, Lee; Vajdic, Claire M.

In: BMJ Open, Vol. 8, No. 6, e021064, 01.06.2018, p. 1-6.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cardiovascular toxicity of targeted therapies for cancer

T2 - BMJ Open

AU - Van Leeuwen, Marina T.

AU - Luu, Steven

AU - Gurney, Howard

AU - Brown, Martin R.

AU - Webber, Kate

AU - Pearson, Sallie-Anne

AU - Hunt, Lee

AU - Vajdic, Claire M.

N1 - Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction: The introduction of targeted therapies for cancer has contributed to dramatic improvements in patient survival. Nevertheless, several targeted therapies have been associated with 'off-target' adverse effects, based on varying levels of evidence. To date, this evidence has not been systematically synthesised. We will synthesise published systematic review evidence of cardiovascular toxicity associated with targeted cancer therapies. Methods and analysis: We will include systematic reviews of randomised controlled trials and observational studies that report on cardiovascular outcomes for individual agents. We will identify systematic reviews by applying predeveloped, standardised search strategies within Embase, Medline and Cochrane Central. Two independent reviewers will identify reviews published up to 31 December 2016 using predefined eligibility criteria. They will resolve ambiguous cases through consensus, arbitrated by a third reviewer if required. The reviewers will extract and report data according to methodological guidelines for overviews provided by the Cochrane Collaboration, Joanna Briggs Institute and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. They will assess the quality of included reviews by applying the Assessment of Multiple Systematic Reviews tool. They will judge the quality of evidence in included reviews based on their assessment of bias and incorporation into the interpretation of findings. In synthesising the evidence, we will classify agents based on systematic review evidence of toxicity (sufficient, probable, possible or indeterminate) for specific cardiovascular outcomes (congestive heart failure, myocardial infarction, ischaemic heart disease, left ventricular ejection fraction decline, cerebrovascular disease, pulmonary embolism, thrombosis and hypertension). This will provide clinicians and patients with an accessible synthesis based on robust methodology. Ethics and dissemination: Ethics approval is not required for overviews. We will conduct the study in collaboration with consumer representatives. We will submit results for peer-review publication, and disseminate them through established clinical and consumer networks. PROSPERO registration number: CRD42017080014.

AB - Introduction: The introduction of targeted therapies for cancer has contributed to dramatic improvements in patient survival. Nevertheless, several targeted therapies have been associated with 'off-target' adverse effects, based on varying levels of evidence. To date, this evidence has not been systematically synthesised. We will synthesise published systematic review evidence of cardiovascular toxicity associated with targeted cancer therapies. Methods and analysis: We will include systematic reviews of randomised controlled trials and observational studies that report on cardiovascular outcomes for individual agents. We will identify systematic reviews by applying predeveloped, standardised search strategies within Embase, Medline and Cochrane Central. Two independent reviewers will identify reviews published up to 31 December 2016 using predefined eligibility criteria. They will resolve ambiguous cases through consensus, arbitrated by a third reviewer if required. The reviewers will extract and report data according to methodological guidelines for overviews provided by the Cochrane Collaboration, Joanna Briggs Institute and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. They will assess the quality of included reviews by applying the Assessment of Multiple Systematic Reviews tool. They will judge the quality of evidence in included reviews based on their assessment of bias and incorporation into the interpretation of findings. In synthesising the evidence, we will classify agents based on systematic review evidence of toxicity (sufficient, probable, possible or indeterminate) for specific cardiovascular outcomes (congestive heart failure, myocardial infarction, ischaemic heart disease, left ventricular ejection fraction decline, cerebrovascular disease, pulmonary embolism, thrombosis and hypertension). This will provide clinicians and patients with an accessible synthesis based on robust methodology. Ethics and dissemination: Ethics approval is not required for overviews. We will conduct the study in collaboration with consumer representatives. We will submit results for peer-review publication, and disseminate them through established clinical and consumer networks. PROSPERO registration number: CRD42017080014.

KW - antineoplastic agent

KW - cancer

KW - cardiovascular toxicity

KW - overview

KW - systematic review

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85049126868&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2017-021064

DO - 10.1136/bmjopen-2017-021064

M3 - Article

VL - 8

SP - 1

EP - 6

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 6

M1 - e021064

ER -